company

SANA PHARMA MANAGEMENT AS

1366 LYSAKER

Return on Equity
−0,07 %
Current Ratio
498,1
Debt-to-Equity Ratio
0
Key figures (NOK)2022
Revenue0
Net Income−22 000
Total Assets30 153 000
Total Equity30 132 000
Income (NOK)2022
Revenue0
Expenditure58 000
Operating Profit−58 000
Financial Income37 000
Financial Costs0
Financial Balance37 000
Earnings Before Tax−22 000
Tax0
Net Income−22 000
Balance (NOK)2022
Total Fixed Assets19 693 000
Total Current Assets10 460 000
Total Assets30 153 000
Total Retained Equity−116 000
Total Equity30 132 000
Total Long-Term Debt0
Total Current Debt21 000
Total Equity and Debt30 153 000
Cash flow (NOK)2022
Sales Income0
Other Income0
Revenue0
Cost of Goods Sold0
Salary Costs0
Depreciation0
Impairment0
Expenditure58 000
Operating Profit−58 000
Financial Income37 000
Financial Costs0
Financial Balance37 000
Dividends0
Net Income−22 000
Balance details (NOK)2022
Goodwill0
Total Intangible Assets0
Real Eastate0
Machinery and Plant Facilities0
Fixtures0
Total Tangible Assets0
Total Fiancial Fixed Assets19 693 000
Total Fixed Assets19 693 000
Stock0
Total Investments0
Cash, Bank28 000
Total Current Assets10 460 000
Total Assets30 153 000
Total Equity30 132 000
Short-Term Group Debt0
Total Long-Term Debt0
Creditors21 000
Unpaid Taxes0
Dividends0
Other Current Debt0
Total Current Debt21 000
Total Equity and Debt30 153 000
Financial indicators2022
Return on Equity−0,07 %
Debt-to-Equity Ratio0
Operating Profit Margin-
Current Ratio498,1
Quick Ratio498,1
Equity Ratio1
Gross Profit Margin-
RotateRotate your device to see the full table
HomeIndustriesNew CompaniesAbout
🇳🇴Norsk🇬🇧English